The Latest Breaking News from Abbott

DALLAS — Texas Attorney General Ken Paxton is attempting for the second time to intervene in a legal fight over gender-affirming medical care at two Dallas hospitals.

With help from La Rabida Children’s Hospital, Zayne Negoski of Joliet got an alternative tube-feeding formula. But his family and those of other medically needy kids have struggled and often had to pay more after Aug. 10 recall.

Leading healthcare company Abbott Laboratories (ABT) reported robust first-quarter results. And the company is well-positioned to benefit from its diversified business. Moreover, as ABT is resuming infant formula production at its Michigan facility, is the stock a good buy at the current price level? Read more to find out….

"I'm going to be on his show on Wednesday, so I might punch him in the face. I don't know, we’ll see what happens.”

Abbott's facility has now closed and reopened twice this year. The baby formula plant had previously closed in February because of bacterial contamination.

Factory in Sturgis, Michigan shut down in May after storms that produced torrential flooding

Abbot Nutrition says baby formula production has resumed at the Michigan plant whose February shutdown over contamination contributed to a national shortage

Diversified healthcare company Abbott (ABT) has demonstrated significant innovations across its segments, and given its dominant market position, the company’s prospects look bright. The stock could be a solid choice as it is well-positioned to survive short-term market fluctuations. Let’s discuss this in detail….

Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in…